Latest News and Events
Filter by
Selections
March 17, 2020
Arrowhead Pharmaceuticals Announces Precautionary Measures to Mitigate Effects of Novel Coronavirus (COVID-19) Spread
Read MoreMarch 3, 2020
Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-HSD in Normal Healthy Volunteers and Patients with NASH or Suspected NASH
Read MoreFebruary 5, 2020
Arrowhead Reports Interim Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3
Read MoreJanuary 6, 2020
Arrowhead Pharmaceuticals Appoints James Hassard as Chief Commercial Officer
Read MoreDecember 20, 2019
Arrowhead Pharmaceuticals Doses First Patient in AROAAT2002 Open Label Phase 2 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Read MoreDecember 16, 2019